GlassScriptPhysician profile
Elmoataz Ibrahim
NPI 1285883371
$2,489.79
in general payments reported to CMS, 2019-2025
24 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,575 · 2020: $320 · 2024: $253 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $352.11 | 2019-2024 | Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $309.05 | 2019-2025 | Austedo Xr |
| Ucb, INC. | $225.17 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Emd Serono, INC. | $189.74 | 2019-2025 | |
| Genzyme Corporation | $187.57 | 2019 | |
| Amgen INC. | $173.85 | 2019-2020 | |
| Abbvie INC. | $155.15 | 2024-2025 | |
| Eisai INC. | $148.72 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $140.09 | 2019-2020 | |
| Biogen, INC. | $102.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $90.16 | 2019-2020 | |
| Acorda Therapeutics, INC | $66.14 | 2019 | |
| Adamas Pharmaceuticals, INC. | $48.68 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $44.42 | 2019 | |
| Pfizer INC. | $33.91 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $32.96 | 2019 | |
| Argenx US, INC. | $31.90 | 2025 | Vyvgart Hytrulo |
| Vertical Pharmaceuticals, LLC | $26.64 | 2019 | |
| Octapharma USA, INC. | $26.53 | 2024 | Panzyga |
| Ipsen Biopharmaceuticals, INC | $24.91 | 2024 | Dysport |
| Jazz Pharmaceuticals INC. | $21.94 | 2024 | |
| Acadia Pharmaceuticals INC | $21.18 | 2025 | Nuplazid |
| Bausch Health US, LLC | $18.87 | 2019 | |
| Allergan, INC. | $17.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elmoataz Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.